While IPA clearly extends lifespan in Drosophila and maintains bone and muscle health in mice [https://pubmed.ncbi.nlm.nih.gov/41540161/], human data remains confusing. We're seeing a total lack of correlation between serum IPA levels and mortality—a discrepancy I call the "IPA Enigma." I suspect this disconnect exists because we haven't accounted for how serum albumin sequesters IPA. Albumin isn't just a reservoir; it’s a selective chaperone that determines whether IPA activates the Pregnane X Receptor (PXR) for repair or triggers Aryl Hydrocarbon Receptor (AhR) toxicity.

I'm proposing a Kinetic Gatekeeper Model where IPA’s longevity effects depend on the Free-to-Total IPA Ratio (FTIR) rather than the total amount in the blood. This ratio dictates mitochondrial proteostasis. Unlike other tryptophan metabolites like indoxyl sulfate, which cause damage through chronic AhR over-activation, IPA seems to operate through a high-affinity, slow-release mechanism.

The mechanics of this likely come down to three factors:

1. Selective Mitophagy Induction: At physiological "free" concentrations (around 500 ng/mL [https://pmc.ncbi.nlm.nih.gov/articles/PMC10223231/]), IPA acts as a PXR agonist in bone and muscle cells. It doesn’t just block NFκB; it triggers a low-level mitochondrial unfolded protein response ($UPR^{mt}$), which essentially cleans up the mitochondria.
2. The Renal-Albumin Pivot: Aging changes things. Declining kidney function and albumin glycation [https://onlinelibrary.wiley.com/doi/full/10.1002/mnfr.202100349] ruin this chaperone effect. When albumin's binding capacity fails, a sudden surge in free IPA creates "signal crowding" at the AhR. This flips the switch from protective signaling to pro-senescent pathways.
3. Barrier-Specific Delivery: IPA-albumin complexes might target tissues with high PXR-mediated transport, like the blood-bone and blood-brain barriers. This explains why IPA levels correlate with bone architecture [https://pmc.ncbi.nlm.nih.gov/articles/PMC12795275/] and lower Aβ accumulation [https://www.science.org/doi/10.1126/sciadv.adw8410] even when systemic levels aren't particularly high.

This is a testable framework. We can re-analyze longitudinal data, like the upcoming NCT06674018 trials, to see if the model holds water. If high free IPA levels don't correlate with younger epigenetic ages (GrimAge) or better mitochondrial efficiency in muscle biopsies, then this "kinetic chaperone" idea is wrong. I'd specifically look at the FTIR in postmenopausal women and correlate it with the $UPR^{mt}$ marker FGF21. My prediction is that the ratio, not the total concentration, will show a significant negative correlation with biological age (p < 0.01).

Critics often argue that IPA is just a byproduct of a healthy microbiome. But if this hypothesis is correct, IPA is a causal kinetic buffer. By controlling the rate of indole delivery to nuclear receptors, the microbiome-host axis actually modulates the pace of mitochondrial decay. It's likely that we aren't seeing a lack of IPA in humans, but rather a total breakdown in its transport kinetics.